Notogen is developing a novel biologic regenerative therapy to treat degenerative disc disease (i.e. chronic back and neck pain as a result of degenerating spinal discs). The product, which is pre-clinical and currently undergoing cGMP manufacturing, is an injectable solution that is fast to administer, cost-effective, and minimally invasive to patients. The unique approach helps the body arrest degeneration and repair and regenerate spinal disc tissues, while reducing pain and inflammation. Based on more than 20 years of clinical and laboratory research, this novel therapeutic has the potential to improve the lives of millions of people worldwide suffering from chronic back and neck pain. Notogen is headquartered in Toronto, Canada.
